Amgen (AMGN) Confirms FDA Approves LUMAKRAS (Sotorasib) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of.
Amgen To Present At The 2021 Jefferies Healthcare Conference prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
This May be a Safer Way for Millions to Treat Arthritic Pain
Millions of people all over the world deal with arthritic pain. In fact, just in the U.S., the Centers for Disease Control and Prevention (CDC), says about 23% of adults are dealing with it. Nearly 24 million are limited with their activities because of it, with about 25% of people reporting severe joint pain. To treat it, millions turn to NSAIDs, or non-steroidal anti-inflammatory drugs, which can actually make things far worse with potential gastrointestinal (GI) issues and intestinal injuries in some cases. However, companies like
Antibe Therapeutics Inc. (TSX: ATE) (OTCQX: ATBPF),
Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, May 11, 2021. David M. Reese, M.D., executive vice president of Research and Development, Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.